Concord Medical Co., Ltd. (TPEX:6518)
Taiwan
· Delayed Price · Currency is TWD 26.60
0.00 (0.00%)
Mar 9, 2026, 2:31 PM CST
Concord Medical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 905.31 | 889.85 | 833.2 | 889.21 | 738.99 | 809.7 | Upgrade
|
| Revenue Growth (YoY) | 4.89% | 6.80% | -6.30% | 20.33% | -8.73% | 6.02% | Upgrade
|
| Cost of Revenue | 788.02 | 780.23 | 731.06 | 780.11 | 670.5 | 745.3 | Upgrade
|
| Gross Profit | 117.29 | 109.62 | 102.15 | 109.1 | 68.49 | 64.41 | Upgrade
|
| Selling, General & Admin | 49.79 | 47.79 | 47.23 | 45 | 32.86 | 36.43 | Upgrade
|
| Operating Expenses | 49.57 | 48.81 | 47.41 | 44.31 | 31.02 | 36.32 | Upgrade
|
| Operating Income | 67.72 | 60.81 | 54.74 | 64.78 | 37.47 | 28.09 | Upgrade
|
| Interest Expense | -3.5 | -3.55 | -3.52 | -3.51 | -4.79 | -6.3 | Upgrade
|
| Interest & Investment Income | 4.27 | 3.99 | 2.87 | 0.9 | 1.03 | 0.79 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | 0.02 | -0.17 | -0.39 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.28 | 1.06 | 0.03 | 0.26 | -0.08 | 1.34 | Upgrade
|
| EBT Excluding Unusual Items | 68.77 | 62.3 | 54.12 | 62.45 | 33.47 | 23.53 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.33 | 0.15 | 0.41 | 1.69 | 9.16 | 1.85 | Upgrade
|
| Other Unusual Items | - | - | - | 0.09 | 0.17 | 0.2 | Upgrade
|
| Pretax Income | 69.1 | 62.45 | 54.53 | 64.22 | 42.79 | 25.57 | Upgrade
|
| Income Tax Expense | 14.41 | 12.88 | 11.78 | 13.58 | 8.39 | 5.8 | Upgrade
|
| Earnings From Continuing Operations | 54.69 | 49.57 | 42.74 | 50.64 | 34.4 | 19.77 | Upgrade
|
| Minority Interest in Earnings | 0.04 | - | - | 0.02 | - | - | Upgrade
|
| Net Income | 54.73 | 49.57 | 42.74 | 50.66 | 34.4 | 19.77 | Upgrade
|
| Net Income to Common | 54.73 | 49.57 | 42.74 | 50.66 | 34.4 | 19.77 | Upgrade
|
| Net Income Growth | 16.45% | 15.97% | -15.62% | 47.27% | 73.96% | -36.99% | Upgrade
|
| Shares Outstanding (Basic) | 33 | 33 | 33 | 33 | 25 | 25 | Upgrade
|
| Shares Outstanding (Diluted) | 33 | 33 | 33 | 33 | 25 | 25 | Upgrade
|
| Shares Change (YoY) | 0.06% | 0.07% | 0.17% | 33.03% | 0.22% | -0.05% | Upgrade
|
| EPS (Basic) | 1.64 | 1.49 | 1.28 | 1.52 | 1.37 | 0.79 | Upgrade
|
| EPS (Diluted) | 1.64 | 1.48 | 1.28 | 1.52 | 1.37 | 0.79 | Upgrade
|
| EPS Growth | 16.31% | 15.63% | -15.77% | 10.93% | 73.42% | -36.80% | Upgrade
|
| Free Cash Flow | 112.81 | 74.12 | 25.05 | 117.1 | 115.63 | -9.58 | Upgrade
|
| Free Cash Flow Per Share | 3.37 | 2.21 | 0.75 | 3.51 | 4.61 | -0.38 | Upgrade
|
| Dividend Per Share | 1.100 | 1.100 | 1.000 | 1.000 | 0.500 | 0.400 | Upgrade
|
| Dividend Growth | 10.00% | 10.00% | - | 100.00% | 25.00% | - | Upgrade
|
| Gross Margin | 12.96% | 12.32% | 12.26% | 12.27% | 9.27% | 7.95% | Upgrade
|
| Operating Margin | 7.48% | 6.83% | 6.57% | 7.29% | 5.07% | 3.47% | Upgrade
|
| Profit Margin | 6.05% | 5.57% | 5.13% | 5.70% | 4.66% | 2.44% | Upgrade
|
| Free Cash Flow Margin | 12.46% | 8.33% | 3.01% | 13.17% | 15.65% | -1.18% | Upgrade
|
| EBITDA | 150.77 | 143.37 | 131.35 | 138.83 | 111.84 | 107.55 | Upgrade
|
| EBITDA Margin | 16.65% | 16.11% | 15.76% | 15.61% | 15.13% | 13.28% | Upgrade
|
| D&A For EBITDA | 83.05 | 82.56 | 76.61 | 74.05 | 74.37 | 79.46 | Upgrade
|
| EBIT | 67.72 | 60.81 | 54.74 | 64.78 | 37.47 | 28.09 | Upgrade
|
| EBIT Margin | 7.48% | 6.83% | 6.57% | 7.29% | 5.07% | 3.47% | Upgrade
|
| Effective Tax Rate | 20.85% | 20.62% | 21.61% | 21.15% | 19.61% | 22.68% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.